Human FCGR3A / CD16a (V158) Protein,also called Human FCGR3A / CD16a Protein (176 Val), Gly 17 - Gln 208 (Accession # AAH17865.1), was produced in human 293 cells (HEK293).
Predicted N Terminal:
Lyophilized from sterile PBS, pH7.4, 10% Trehalose.
Measured by its binding ability in a functional ELISA. Immobilized Yervoy Ipilimumab (Human IgG1) at 5 μg/mL (100 μL/well) can bind Human FCGR3A / CD16a (V158), His Tag with a linear range of 1-16 ng/mL. The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay. Immobilized Human FCGR3A / CD16a (V158), His Tag can bind Ipilimumab with affinity constant of around 171 nM.
Human FCGR3A / CD16a (V158), His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 23.7 kDa. The reducing protein migrates as 40-50 kDa in SDS-PAGE due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by reduced SDS-PAGE.
Samples are stable for up to twelve months from date of receipt at -70ºC.
Store it under sterile conditions at -20ºC~-70ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4ºC before opening to recover the entire contents.